U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Primary Peritoneal Serous Adenocarcinoma

MedGen UID:
1755587
•Concept ID:
C5418959
•
Neoplastic Process

Definition

Primary peritoneal serous adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Primary Peritoneal Serous Adenocarcinoma

Recent clinical studies

Etiology

HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
Jou J, Zimmer Z, Charo L, Yau C, Saenz C, Eskander R, McHale M, Veerapong J, Plaxe S, Binder P
Gynecol Oncol 2021 Apr;161(1):25-33. Epub 2020 Dec 6 doi: 10.1016/j.ygyno.2020.11.035. PMID: 33293046
Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Emons G, Gorchev G, Sehouli J, Wimberger P, Stähle A, Hanker L, Hilpert F, Sindermann H, Gründker C, Harter P
Gynecol Oncol 2014 Jun;133(3):427-32. Epub 2014 Apr 5 doi: 10.1016/j.ygyno.2014.03.576. PMID: 24713545
Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD
Int J Gynecol Cancer 2009 Jul;19(5):860-6. doi: 10.1111/IGC.0b013e3181a8331f. PMID: 19574774
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR
J Clin Oncol 2003 Jan 15;21(2):283-90. doi: 10.1200/JCO.2003.10.104. PMID: 12525520

Diagnosis

Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM
J Clin Oncol 2003 Jan 15;21(2):291-7. doi: 10.1200/JCO.2003.02.091. PMID: 12525521

Therapy

HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
Jou J, Zimmer Z, Charo L, Yau C, Saenz C, Eskander R, McHale M, Veerapong J, Plaxe S, Binder P
Gynecol Oncol 2021 Apr;161(1):25-33. Epub 2020 Dec 6 doi: 10.1016/j.ygyno.2020.11.035. PMID: 33293046
Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Emons G, Gorchev G, Sehouli J, Wimberger P, Stähle A, Hanker L, Hilpert F, Sindermann H, Gründker C, Harter P
Gynecol Oncol 2014 Jun;133(3):427-32. Epub 2014 Apr 5 doi: 10.1016/j.ygyno.2014.03.576. PMID: 24713545
Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD
Int J Gynecol Cancer 2009 Jul;19(5):860-6. doi: 10.1111/IGC.0b013e3181a8331f. PMID: 19574774
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM
J Clin Oncol 2003 Jan 15;21(2):291-7. doi: 10.1200/JCO.2003.02.091. PMID: 12525521
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR
J Clin Oncol 2003 Jan 15;21(2):283-90. doi: 10.1200/JCO.2003.10.104. PMID: 12525520

Prognosis

Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD
Int J Gynecol Cancer 2009 Jul;19(5):860-6. doi: 10.1111/IGC.0b013e3181a8331f. PMID: 19574774
Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms.
Bidus MA, Webb JC, Seidman JD, Rose GS, Boice CR, Elkas JC
Gynecol Oncol 2006 Jul;102(1):5-7. Epub 2006 May 12 doi: 10.1016/j.ygyno.2006.03.048. PMID: 16697451

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...